26.56

1.37% -0.37

After Hours: 26.62 0.06 +0.23%

Maze Therapeutics Inc (MAZE)

Overview News Price History Discussions Forecast

Maze Therapeutics Inc stock is traded at $26.56, with a volume of 557.41K. It is down -1.37% in the last 24 hours and down -7.49% over the past month. Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.

Previous Close:

$26.93

Open:

$27.15

24h Volume:

557.41K

Relative Volume:

0.65

Market Cap:

$1.47B

Revenue:

$2.50M

Net Income/Loss:

$-131.12M

P/E Ratio:

-9.3419

EPS:

-2.8431

Net Cash Flow:

$-112.73M

1W Performance:

+2.35%

1M Performance:

-7.49%

6M Performance:

-12.26%

1Y Performance:

+154.89%

1-Day Range:

$26.12

$27.58

1-Week Range:

$25.08

$28.18

52-Week Range:

$8.245

$53.65

Maze Therapeutics Inc Stock (MAZE) Company Profile

Name

Maze Therapeutics Inc

Sector

Healthcare (1106)

Industry

Biotechnology (615)

Phone

(650) 850-5070

Address

171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO

Employee

141

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

MAZE's Discussions on Twitter

Compare MAZE vs VRTX, REGN, ARGX, ALNY, ONC

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
MAZE Maze Therapeutics Inc	26.56	1.49B	2.50M	-131.12M	-112.73M	-2.8431
VRTX Vertex Pharmaceuticals Inc	424.36	109.34B	12.32B	4.34B	3.19B	16.86
REGN Regeneron Pharmaceuticals Inc	702.27	74.35B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	794.70	50.44B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	301.11	39.78B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	297.49	33.02B	5.36B	287.73M	924.18M	2.5229

Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-18-26	Initiated	Truist	Buy
Mar-10-26	Initiated	Mizuho	Outperform
Dec-04-25	Initiated	Wells Fargo	Overweight
Nov-14-25	Initiated	Raymond James	Outperform
Sep-02-25	Initiated	BTIG Research	Buy
Jul-23-25	Initiated	H.C. Wainwright	Buy
Jul-08-25	Initiated	Wedbush	Outperform

View All

Maze Therapeutics Inc Stock (MAZE) Latest News

May 01, 2026

Maze Therapeutics (MAZE) CSBO exercises options, sells 7,500 shares under 10b5-1 plan - Stock Titan

May 01, 2026

MAZE Stock Price, Quote & Chart | MAZE THERAPEUTICS INC (NASDAQ:MAZE) - ChartMill

May 01, 2026

Apr 30, 2026

MAZE SEC FilingsMaze Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan

Apr 30, 2026

Apr 29, 2026

After plunging 30.8% in 4 weeks, here's why the trend might reverse for Maze Therapeutics, Inc. (MAZE) - MSN

Apr 29, 2026

Apr 28, 2026

Maze Therapeutics (NASDAQ: MAZE) details 2026 proxy, board slate and executive pay - Stock Titan

Apr 28, 2026

Apr 27, 2026

Maze Therapeutics (MAZE) price target increased by 19.51% to 61.71 - MSN

Apr 27, 2026

Apr 26, 2026

Maze Therapeutics Stock Surges with 150 Percent Upside Potential - HarianBasis.co

Apr 26, 2026

What Makes Maze Therapeutics (MAZE) One of the Best Oversold Small-Cap Stocks to Buy - Yahoo Finance

Apr 26, 2026

Apr 25, 2026

5 Oversold Small Cap Stocks to Buy Now - Insider Monkey

Apr 25, 2026

Maze Therapeutics shares surge after positive Phase 2 data for MZE829 - MSN

Apr 25, 2026

Maze Therapeutics Raises Fresh Capital As R&D Plans And Valuation Diverge - Sahm

Apr 25, 2026

Apr 23, 2026

Maze Therapeutics falls despite positive mid-stage trial data for lead asset - MSN

Apr 23, 2026

Maze Therapeutics prices $150M equity offering - MSN

Apr 23, 2026

Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN

Apr 23, 2026

Apr 22, 2026

Maze Therapeutics prices $150 million equity offering - TipRanks

Apr 22, 2026

Maze Therapeutics prices $150M registered offering; expects ~$144.7M net proceeds, funds into 2029 - TradingView

Apr 22, 2026

[8-K] Maze Therapeutics, Inc. Reports Material Event - Stock Titan

Apr 22, 2026

[424B5] Maze Therapeutics, Inc. Prospectus Supplement (Debt Securities) - Stock Titan

Apr 22, 2026

Maze Therapeutics (NASDAQ:MAZE) Shares Gap UpHere's Why - MarketBeat

Apr 22, 2026

Maze Therapeutics (MAZE) Stock: Momentum Shift Insight (Rocket Higher) 2026-04-22Professional Trade Ideas - UBND thành phố Hải Phòng

Apr 22, 2026

MAZE Secures Investment from Notable Funds - GuruFocus

Apr 22, 2026

Maze Therapeutics priced offering of 5.54M shares of common stock at $23.50 - TipRanks

Apr 22, 2026

Maze Therapeutics Intends to Use Any Net Proceeds From Offering to Advance R&D of Its Product Candidates >MAZE - Moomoo

Apr 22, 2026

Maze Therapeutics Prices Public Offering of 5,540,000 Shares at $23.50 Per Share, Aiming for $150 Million in Gross Proceeds - Quiver Quantitative

Apr 22, 2026

Maze Therapeutics announces $150 million registered offering - marketscreener.com

Apr 22, 2026

Maze Therapeutics Announces $150 Million Registered Offering - TradingView

Apr 22, 2026

Fenwick Represents Maze Therapeutics in $150M Underwritten Offering - fenwick.com

Apr 22, 2026

Apr 21, 2026

239,994 Shares in Maze Therapeutics, Inc. $MAZE Acquired by Mass General Brigham Inc - MarketBeat

Apr 21, 2026

Apr 20, 2026

Truist Updates Maze Therapeutics, Inc. (MAZE) Model for Share Count and Warrant Impact - Insider Monkey

Apr 20, 2026

Is Maze Therapeutics (MAZE) stock holding its gains (-0.96%) 2026-04-20High Volume Stocks - UBND thành phố Hải Phòng

Apr 20, 2026

Apr 18, 2026

Maze Therapeutics (NASDAQ:MAZE) Downgraded to "Sell" Rating by Wall Street Zen - MarketBeat

Apr 18, 2026

Apr 17, 2026